Arvinas' Participation in Investor Conferences
Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company focused on developing innovative therapies using targeted protein degradation, is gearing up to participate in some important investor conferences. This participation underscores Arvinas' commitment to advancing its groundbreaking initiatives and engaging with the investment community actively.
Upcoming Conferences and Presentations
Management from Arvinas will take part in two significant investor conferences designed to foster deeper connections and share insights on its development programs:
Wells Fargo Healthcare Conference
The first of these events is the Wells Fargo Healthcare Conference, scheduled for early September. During this conference, a live audio webcast of the presentation will be made available, allowing for broader access to those interested in learning about Arvinas' strategic plans and pipeline advancements.
Cantor Global Healthcare Conference
Following the Wells Fargo event, Arvinas will also be featured at the Cantor Global Healthcare Conference. Similar to the previous event, a live audio webcast will be provided, making it easy for investors to tune in and gain valuable insights into the company's future direction.
About Arvinas and Its Innovative Approach
Established with the vision to transform treatment paradigms, Arvinas is pioneering a new class of therapeutics based on its proprietary PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. This cutting-edge technology leverages the body's natural protein degradation systems, offering a novel approach to target and eliminate disease-causing proteins effectively.
Current Developments and Clinical Trials
Arvinas is advancing multiple investigational drugs through various clinical development programs. Among these therapies is vepdegestrant, which targets the estrogen receptor, specifically designed for patients with advanced or metastatic ER+/HER2- breast cancer. Additionally, ARV-393 aims at BCL6 for relapsed/refractory non-Hodgkin Lymphoma, while ARV-102 targets LRRK2 for neurodegenerative disorders. Another promising asset, ARV-806, is focused on KRAS G12D mutations prevalent in cancers such as pancreatic and colorectal types.
Connecting with Stakeholders
To learn more about Arvinas and its promising pipeline of therapies, stakeholders and interested parties are encouraged to visit the company’s official website. Staying informed through the latest updates will provide valuable perspectives on the company’s growth trajectory and its potential impact on improving patient outcomes across various serious medical conditions.
Contacting Arvinas
For investor inquiries, Arvinas offers direct contact through Jeff Boyle, available at +1 (347) 247-5089 or via email. Media inquiries can be directed to Kirsten Owens at +1 (203) 584-0307. They can provide detailed answers to those interested in the company’s strategic goals and advancements in research and development.
Frequently Asked Questions
What is Arvinas known for?
Arvinas is a biotechnology firm that focuses on developing therapies through targeted protein degradation, offering innovative treatments for various diseases.
What conferences is Arvinas participating in?
Arvinas will participate in the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference.
How does the PROTAC technology work?
PROTAC technology is designed to utilize the body's natural processes to selectively target and degrade proteins associated with diseases.
What are some of Arvinas' key drug candidates?
Key candidates include vepdegestrant for breast cancer and ARV-393 for lymphoma, alongside others targeting neurodegenerative diseases and certain cancers.
How can I contact Arvinas for more information?
You can reach out to investor relations via Jeff Boyle or media inquiries through Kirsten Owens, both accessible through provided contact information.
